PA-GROVARA
24.3.2021 17:08:09 CET | Business Wire | Press release
Grovara, the largest B2B global marketplace for U.S. natural and organic brands, announced today the closing of a $5.5 million seed round financing to transform global commerce. David Pottruck led the round and was named Executive Chairman, and he was joined by SPINS, Bluestein Ventures, Spiral Sun Ventures, Siddhi Capital, CEAS Investments, and E and A Venture Capital LLC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005746/en/
The new investment will be used to expand sales and support resources in key regions worldwide and appoint leadership for brands, sales, and business development. Grovara will also invest in additional supply chain team members, roll out marketing initiatives, develop global partnerships, and continue with product enhancements to its first-to-market technology platform.
“We are happy to be joined by new investors and continue with some long-term partners who have helped us get to this point,” says Grovara Co-Founder and now CEO Abu Kamara, who previously served as Grovara’s President. “Grovara is transforming global commerce for U.S. consumer brands with the first B2B global marketplace for U.S. natural and organic brands. When you lower barriers and simplify exporting to a marketplace, you create tremendous opportunities for brands and retailers to grow their business. It's a game-changer.”
The bridge round comes at a time when the natural and organic food and beverage market and B2B ecommerce are surging. The global natural & organic products market is worth $327B with U.S. brands accounting for $110B, while a recent study of global B2B buyers found 87% of them are purchasing from online marketplaces .
“For as challenging as the last year has been, it has greatly accelerated wellness and digital transformation. Our online B2B global marketplace is positioned perfectly to shepherd this growth and put the healthiest, highest-quality products in front of more retailers who previously did not have access,” says Grovara Co-Founder Peter Groverman, who stepped away from his CEO role to fill the newly created Chief Innovation Officer position. “With this funding round, we can accelerate the onboarding of brands and buyers in our ecosystem to discover, connect and grow their international business.”
In 2020, Grovara launched its technology platform and despite the disruption related to the coronavirus pandemic, continued to grow its portfolio. In 2021, the company anticipates onboarding 200 new brands and 350 additional retailers.
Grovara’s platform, built on a decade of exporting experience, brings access, visibility, and transparency to both brands and buyers via pricing, brand and market insights, and a modern B2C user experience for B2B business.
Nine out of 10 U.S. wellness brands do not export their products, primarily due to the complexities and risks of international business. Grovara’s technology platform is built to manage the export lifecycle and provide wellness-focused, insights-driven data that accelerates growth and scale. Grovara connects major U.S. natural and organic brands like GT’s Living Foods , Wholesome Sweeteners , Honey Stinger , True Citrus , and That’s It with key global retailers like Walmart Mexico , Cencosud , Whole Foods U.K. , and Costco Taiwan .
“My career has been focused on transformational technology and how consumers and businesses use it to create better outcomes,” says Pottruck, former CEO of Charles Schwab. “It’s easy to see how Grovara is well-positioned for this moment with the best technology, the most authority, and industry-leading partners.”
Grovara was recently named a finalist for the Philadelphia Alliance for Capital and Technology (PACT) Enterprise Awards , to be held on June 28, in the Technology Startup category.
ABOUT GROVARA : Grovara is the first B2B global marketplace for natural and organic brands. Grovara increases access to wellness products for global consumers with its proprietary technology platform that connects the most promising U.S. healthy consumer brands with vetted global retailers. With only 1 in 10 wellness brands selling overseas, Grovara enables exporting with visibility, transparency and an intuitive user experience, creating a pathway for dynamic growth potential for American manufacturers and added value for worldwide retailers. More information on Grovara’s market-leading processes and partners can be found at www.grovara.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005746/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom